Intravascular clot formation is an important event in a number of cardiovascular diseases.
The prevention of blood coagulation has become a major target for new therapeutic agents …

Background: Despite the introduction of direct oral anticoagulants, the search for new oral
anticoagulants remains an urgent task. Objective: By using docking and scoring, based on …

Derivatives of (2-amidino-1, 2, 3, 4-tetrahydro-isoquinolin-7-yloxy) phenylacetic acid (TIPAC)
were developed as inhibitors of factor Xa (fXa). The compounds are prepared using 15 …

In the early 1990's, we reported on the low-molecular selective fXa inhibitor DX-9065a
having two amidino groups. However, it had poor oral bioavailability due to its strong basic …

Thrombosis is a major cause of mortality in the industrialized world. Therefore, the control of
blood coagulation has become a major target for new therapeutic agents. One attractive …

Monoamidine FXa inhibitors 3 were designed and synthesized. SAR studies and molecular
modeling led to the design of conformationally constrained diaryl ethers 4 and 5, as well as …

Direct oral anticoagulants are an important and relatively new class of synthetic
anticoagulant drugs commonly used for the pharmacotherapy of thromboembolic disorders …

Factor Xa plays an important role in blood coagulation and is widely regarded as an
attractive target for antithrombotic drug development. M55551 and M55165 (1-arylsulfonyl-3 …

Abstract Factor Xa (FXa) is an enzyme belonging to the serine protease family which plays a
vital role in hemostasis, being an essential part in the blood-clotting cascade by catalyzing …

Thrombotic diseases are a major cause of death and morbidity. Factor Xa (fXa) plays a vital
role in the regulation of normal homeostasis and abnormal intravascular thrombus …